The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients
Open accessAbstract
CONTEXT: Cytomegalovirus (CMV) infection is associated with adverse clinical outcomes in immunosuppressed persons, but the incidence and association of CMV reactivation with adverse outcomes in critically ill persons lacking evidence of immunosuppression have not been well defined. OBJECTIVE: To determine the association of CMV reactivation with intensive care unit (ICU) and hospital length of stay in critically ill immunocompetent persons. DESIGN, SETTING, AND PARTICIPANTS: We prospectively assessed CMV plasma DNAemia by thrice-weekly real-time polymerase chain reaction (PCR) and clinical outcomes in a cohort of 120 CMV-seropositive, immunocompetent adults admitted to 1 of 6 ICUs at 2 separate hospitals at a large US tertiary care academic medical center between 2004 and 2006. Clinical measurements were assessed by personnel blinded to CMV PCR results. Risk factors for CMV reactivation and association with hospital and ICU length of stay were assessed by multivariable logistic regression and proportional odds models. MAIN OUTCOME MEASURES: Association of CMV reactivation with prolonged hospital length of stay or death. RESULTS: The primary composite end point of continued hospitalization (n = 35) or death (n = 10) by 30 days occurred in 45 (35%) of the 120 patients. Cytomegalovirus viremia at any level occurred in 33% (39/120; 95% confidence interval [CI], 24%-41%) at a median of 12 days (range, 3-57 days) and CMV viremia greater than 1000 copies/mL occurred in 20% (24/120; 95% CI, 13%-28%) at a median of 26 days (range, 9-56 days). By logistic regression, CMV infection at any level (adjusted odds ratio [OR], 4.3; 95% CI, 1.6-11.9; P = .005) and at greater than 1000 copies/mL (adjusted OR, 13.9; 95% CI, 3.2-60; P < .001) and the average CMV area under the curve (AUC) in log(10) copies per milliliter (adjusted OR, 2.1; 95% CI, 1.3-3.2; P < .001) were independently associated with hospitalization or death by 30 days. In multivariable partial proportional odds models, both CMV 7-day moving average (OR, 5.1; 95% CI, 2.9-9.1; P < .001) and CMV AUC (OR, 3.2; 95% CI, 2.1-4.7; P < .001) were independently associated with a hospital length of stay of at least 14 days. CONCLUSIONS: These preliminary findings suggest that reactivation of CMV occurs frequently in critically ill immunocompetent patients and is associated with prolonged hospitalization or death. A controlled trial of CMV prophylaxis in this setting is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
Baker, S. P., O’Neill, B., Haddon, W. F., & Long, W. B. (1974) · PubMed · Cited by 7,946
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Infection in Organ-Transplant Recipients
Fishman, J. A., & Rubin, R. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806113382407 · Cited by 1,622
APACHE II-A Severity of Disease Classification System
Gall, J.-R. L., Loirat, P., & Alpcrovitch, A. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00027 · Cited by 1,236
Clinical and economic consequences of ventilator-associated pneumonia: A systematic review
Safdar, N., Dezfulian, C., Collard, H. R., & Saint, S. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000181731.53912.d9 · Cited by 1,086
Pittet, D. (1994) · JAMA · doi:10.1001/jama.1994.03510440058033 · Cited by 926
Partial Proportional Odds Models for Ordinal Response Variables
Peterson, B., & Harrell, F. E. (1990) · Applied Statistics · doi:10.2307/2347760 · Cited by 813
Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation
Lowance, D., Neumayer, H.-H., Legendre, C. M., Squifflet, J.-P., Kovarik, J., Brennan, P. J., Norman, D., Mendez, R., Keating, M. R., Coggon, G. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401903 · Cited by 712
Cited by
Severe Sepsis and Septic Shock
Angus, D. C., & van der Poll, T. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1208623 · Cited by 3,961
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · Nature Reviews Immunology · doi:10.1038/nri3552 · Cited by 2,772
Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure
Boomer, J. S., To, K., Chang, K. C., Takasu, O., Osborne, D. F., Walton, A. H., Bricker, T. L., Jarman, S. D., Kreisel, D., Krupnick, A. S., et al. (2011) · JAMA · doi:10.1001/jama.2011.1829 · Cited by 1,781
Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70001-x · Cited by 1,442
Age-dependent dysregulation of innate immunity
Shaw, A. C., Goldstein, D. R., & Montgomery, R. R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3547 · Cited by 1,061
Ventilator-associated pneumonia in adults: a narrative review
Papazian, L., Klompas, M., & Luyt, C.-E. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05980-0 · Cited by 1,010
EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure
Wendon, J., Cordoba, J., Dhawan, A., Larsen, F. S., Manns, M., Nevens, F., Samuel, D., Simpson, K. J., Yaron, I., & Bernardi, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.003 · Cited by 917
The immune system’s role in sepsis progression, resolution, and long-term outcome
Delano, M. J., & Ward, P. A. (2016) · Immunological Reviews · doi:10.1111/imr.12499 · Cited by 880
A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1
Pillay, J., Kamp, V. M., van Hoffen, E., Visser, T., Tak, T., Lammers, J.-W., Ulfman, L. H., Leenen, L. P., Pickkers, P., & Koenderman, L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57990 · Cited by 828
Sepsis-induced immune dysfunction: can immune therapies reduce mortality?
Delano, M. J., & Ward, P. A. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82224 · Cited by 644
The sepsis seesaw: tilting toward immunosuppression
Hotchkiss, R. S., Coopersmith, C. M., McDunn, J. E., & Ferguson, T. A. (2009) · Nature Medicine · doi:10.1038/nm0509-496 · Cited by 574
New Approaches to Sepsis: Molecular Diagnostics and Biomarkers
Reinhart, K., Bauer, M., Riedemann, N. C., & Hartog, C. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00016-12 · Cited by 533
Mira, J. C., Gentile, L. F., Mathias, B. J., Efron, P. A., Brakenridge, S. C., Mohr, A. M., Moore, F. A., & Moldawer, L. L. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002074 · Cited by 526
Reactivation of Multiple Viruses in Patients with Sepsis
Walton, A. H., Muenzer, J. T., Rasche, D., Boomer, J. S., Sato, B., Brownstein, B. H., Pachot, A., Brooks, T. L., Deych, E., Shannon, W. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098819 · Cited by 411
Pathological alteration and therapeutic implications of sepsis-induced immune cell apoptosis
Cao, C., Yu, M., & Chai, Y. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2015-1 · Cited by 354
Epidemiology and Immune Pathogenesis of Viral Sepsis
Lin, G.-L., McGinley, J. P., Drysdale, S. B., & Pollard, A. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02147 · Cited by 351
Hunt, P. W., Martin, J. N., Sinclair, E., Epling, L., Teague, J., Jacobson, M. A., Tracy, R. P., Corey, L., & Deeks, S. G. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir060 · Cited by 344
Cytomegalovirus and human immunosenescence
Pawelec, G., Derhovanessian, E., Larbi, A., Strindhall, J., & Wikby, A. (2009) · Reviews in Medical Virology · doi:10.1002/rmv.598 · Cited by 338
Blot, S., Ruppé, E., Harbarth, S., Asehnoune, K., Poulakou, G., Luyt, C.-E., Rello, J., Klompas, M., Depuydt, P., Eckmann, C., et al. (2022) · Intensive and Critical Care Nursing · doi:10.1016/j.iccn.2022.103227 · Cited by 333
Cannon, M. J., Hyde, T. B., & Schmid, D. S. (2011) · Reviews in Medical Virology · doi:10.1002/rmv.695 · Cited by 316
Brahmamdam, P., Inoue, S., Unsinger, J., Chang, K. C., McDunn, J. E., & Hotchkiss, R. S. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0110037 · Cited by 305
Barbier, F., Andremont, A., Wolff, M., & Bouadma, L. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32835f27be · Cited by 281
Clinical review: Blood purification for sepsis
Rimmel�, T., & Kellum, J. A. (2011) · Critical Care · doi:10.1186/cc9411 · Cited by 279
Wang, G. C., Kao, W. H. L., Murakami, P., Xue, Q.-L., Chiou, R. B., Detrick, B., McDyer, J. F., Semba, R. D., Casolaro, V., Walston, J. D., et al. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwq062 · Cited by 265
Cytomegalovirus Latency and Reactivation: An Intricate Interplay With the Host Immune Response
Forte, E., Zhang, Z., Thorp, E. B., & Hummel, M. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00130 · Cited by 256
Fever in the critically ill medical patient
Laupland, K. B. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181aa6117 · Cited by 139
“However, there has been increasing recognition of the role of reactivation of latent herpes viruses, most notably herpes simplex virus and cytomegalovirus, as causes of febrile infections with onset after admission to ICU (24, 25).”
BackgroundKadambari, S., Klenerman, P., & Pollard, A. J. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2144 · Cited by 118
Huang, T.-S., Shyu, Y.-C., Chen, H.-Y., Lin, L.-M., Lo, C.-Y., Yuan, S.-S., & Chen, P.-J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054431 · Cited by 108
Derhovanessian, E., Maier, A. B., Hähnel, K., Zelba, H., de Craen, A. J. M., Roelofs, H., Slagboom, E. P., Westendorp, R. G. J., & Pawelec, G. (2013) · AGE · doi:10.1007/s11357-012-9425-7 · Cited by 102
“The ability to mount a pro-inflammatory response in the absence of an anti-inflammatory response would also help protect against re-infection with any other pathogen, conferring a survival benefit.”
Reeves, M. B., Breidenstein, A., & Compton, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114966108 · Cited by 82
Waldrop, G., Zucker, J., Boubour, A., Radmard, S., Green, D. A., & Thakur, K. T. (2022) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0380-oa · Cited by 22
Towards personalized medicine in sepsis: quest for Shangri-La?
Sen, A., & Yende, S. (2013) · Critical Care · doi:10.1186/cc12485 · Cited by 11
“Subsequent theories have proposed that some patients may be immuno suppressed and the compensatory anti-infl ammatory response syndrome may predominate [7-9], leading to secondary infections and reactivation of dormant viruses [10,11].”
Metadata
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2008-07-23
- Volume
- 300
- Issue
- 4
- Pages
- 413
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1492950536
- Cited by
- 572
- References
- 30
- FWCI
- 26.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.